Oslo, Norway, 6 February 2025
Vistin Pharma ASA will release its fourth quarter and preliminary 2024 results on Thursday 13th of February 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion.
The conference call will be held in English.
The fourth quarter conference call will be available via web and audio through the following access points:
Webcast: https://edge.media-server.com/mmc/p/ekueptdm
Telephone conference (online registration):
https://register.vevent.com/register/BI6693743078794f05ac2e84522925591f
*****
For further information, please contact:
Alexander Karlsen
CFO
+47 97053621
About Vistin Pharma | www.vistin.com
Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
